Christopher A. French

14.7k total citations
109 papers, 6.7k citations indexed

About

Christopher A. French is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Christopher A. French has authored 109 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Molecular Biology, 46 papers in Hematology and 27 papers in Oncology. Recurrent topics in Christopher A. French's work include Protein Degradation and Inhibitors (81 papers), Ubiquitin and proteasome pathways (62 papers) and Multiple Myeloma Research and Treatments (46 papers). Christopher A. French is often cited by papers focused on Protein Degradation and Inhibitors (81 papers), Ubiquitin and proteasome pathways (62 papers) and Multiple Myeloma Research and Treatments (46 papers). Christopher A. French collaborates with scholars based in United States, Canada and Italy. Christopher A. French's co-authors include Jonathan A. Fletcher, Jon C. Aster, Antonio R. Pérez‐Atayde, I Miyoshi, Michael J. Cameron, Edward B. Stelow, Ichiro Kubonishi, Jeffery L. Kutok, Holcombe E. Grier and Sara O. Vargas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Christopher A. French

108 papers receiving 6.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher A. French United States 43 5.1k 2.4k 1.7k 835 681 109 6.7k
Jo‐Anne Vergilio United States 26 1.1k 0.2× 661 0.3× 1.1k 0.7× 711 0.9× 679 1.0× 118 3.9k
Kai Neben Germany 41 2.3k 0.4× 2.5k 1.0× 1.5k 0.9× 270 0.3× 194 0.3× 111 4.2k
Iwona Włodarska Belgium 52 2.2k 0.4× 1.5k 0.6× 3.2k 1.8× 610 0.7× 859 1.3× 193 8.6k
Sa A. Wang United States 38 940 0.2× 3.2k 1.3× 1.2k 0.7× 251 0.3× 354 0.5× 280 5.4k
Günter Schlimok Germany 32 1.8k 0.4× 780 0.3× 3.9k 2.2× 497 0.6× 1.3k 1.9× 79 6.4k
Harald Rieder Germany 31 1.1k 0.2× 1.0k 0.4× 1.2k 0.7× 586 0.7× 156 0.2× 84 3.5k
Hartmut Kirchner Germany 32 1.3k 0.3× 1.0k 0.4× 1.9k 1.1× 363 0.4× 997 1.5× 117 5.0k
Patricia T. Greipp United States 27 901 0.2× 972 0.4× 631 0.4× 337 0.4× 415 0.6× 142 2.4k
Mark Kirschbaum United States 25 1.9k 0.4× 3.2k 1.3× 2.1k 1.2× 130 0.2× 335 0.5× 66 6.2k
Jennifer H. Yearley United States 24 1.1k 0.2× 360 0.1× 3.7k 2.1× 653 0.8× 1.4k 2.0× 56 5.7k

Countries citing papers authored by Christopher A. French

Since Specialization
Citations

This map shows the geographic impact of Christopher A. French's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. French with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. French more than expected).

Fields of papers citing papers by Christopher A. French

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher A. French. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. French. The network helps show where Christopher A. French may publish in the future.

Co-authorship network of co-authors of Christopher A. French

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher A. French. A scholar is included among the top collaborators of Christopher A. French based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher A. French. Christopher A. French is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahadevan, Navin R., Paul K. Paik, Jamie E. Chaft, et al.. (2025). Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry. Clinical Cancer Research. 31(18). 3922–3931. 2 indexed citations
2.
Luo, Jia, Mark G. Evans, Tolulope Adeyelu, et al.. (2024). Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma. JCO Precision Oncology. 8(8). e2400334–e2400334. 2 indexed citations
3.
Luo, Jia, Paul K. Paik, Jamie E. Chaft, et al.. (2024). Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry.. Journal of Clinical Oncology. 42(16_suppl). 8553–8553. 1 indexed citations
4.
Cheng, Michael L., Jaclyn LoPiccolo, Mizuki Nishino, et al.. (2023). Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO Precision Oncology. 7(7). e2200633–e2200633. 4 indexed citations
5.
Becker, Simone, et al.. (2023). Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report. JTO Clinical and Research Reports. 5(1). 100625–100625. 1 indexed citations
6.
Huang, Julianna, Luke Wojenski, Prafulla C. Gokhale, et al.. (2023). The BRD4–NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma. Cancer Research. 83(23). 3846–3860. 11 indexed citations
7.
Bhindi, Bimal, Girish S. Kulkarni, D. Robert Siemens, et al.. (2021). Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version. Canadian Urological Association Journal. 15(8). 230–9. 9 indexed citations
8.
Shiota, Hitoshi, Artyom A. Alekseyenko, Zhipeng A. Wang, et al.. (2021). Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment. Molecular Cancer Research. 19(11). 1818–1830. 13 indexed citations
9.
Kuo, Lindsay E., Justine A. Barletta, Jonathan D. Schoenfeld, et al.. (2021). NUT Carcinoma of the Thyroid: An Unusual Case with a Complete Response to Treatment. Clinical Thyroidology. 33(1). 38–47. 6 indexed citations
10.
Soroko, Kara M., Benjamin K. Eschle, Margaret K. Wilkens, et al.. (2020). Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Molecular Cancer Therapeutics. 19(7). 1406–1414. 58 indexed citations
11.
Bayrak, Büşra Yaprak, et al.. (2020). Nuclear protein in testis midline carcinoma in a Turkish boy: a case report. Asian Biomedicine. 14(5). 203–208. 1 indexed citations
12.
Chau, Nicole G., Clement Ma, Hasan Al‐Sayegh, et al.. (2019). An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectrum. 4(2). pkz094–pkz094. 131 indexed citations
13.
Stathis, Anastasios, Emanuele Zucca, Mohamed Békradda, et al.. (2016). Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discovery. 6(5). 492–500. 268 indexed citations
14.
Strickland, Kyle C., Marina Vivero, Vickie Y. Jo, et al.. (2016). Preoperative Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Prospective Analysis. Thyroid. 26(10). 1466–1471. 83 indexed citations
15.
Wang, Ranran, Wei Liu, James E. Bradner, et al.. (2014). Activation of SOX2 Expression by BRD4-NUT Oncogenic Fusion Drives Neoplastic Transformation in NUT Midline Carcinoma. Cancer Research. 74(12). 3332–3343. 45 indexed citations
16.
French, Christopher A., Shaila Rahman, Erica M. Walsh, et al.. (2014). NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism. Cancer Discovery. 4(8). 928–941. 186 indexed citations
17.
Bauer, Daniel E., Chelsey M. Mitchell, Kelly M. Strait, et al.. (2012). Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. Clinical Cancer Research. 18(20). 5773–5779. 276 indexed citations
18.
Schwartz, Brian E., Matthias D. Hofer, Madeleine E. Lemieux, et al.. (2011). Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. Cancer Research. 71(7). 2686–2696. 156 indexed citations
19.
Reynoird, Nicolas, Brian E. Schwartz, Karin Sadoul, et al.. (2010). Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. The EMBO Journal. 29(17). 2943–2952. 142 indexed citations
20.
French, Christopher A., Cherie L. Ramirez, Tyler Hickman, et al.. (2007). BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 27(15). 2237–2242. 323 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jo‐Anne Vergilio Breakdown of academic impact, for papers by Kai Neben Breakdown of academic impact, for papers by Iwona Włodarska Breakdown of academic impact, for papers by Sa A. Wang Breakdown of academic impact, for papers by Günter Schlimok Breakdown of academic impact, for papers by Harald Rieder Breakdown of academic impact, for papers by Hartmut Kirchner Breakdown of academic impact, for papers by Patricia T. Greipp Breakdown of academic impact, for papers by Mark Kirschbaum Breakdown of academic impact, for papers by Jennifer H. Yearley
Rankless by CCL
2026